Hyderabad, February 9, 2025
Rainbow Children’s Medicare Limited (NSE: RAINBOW, BSE: 543524) has reported robust financial results for the quarter and nine months ended December 31, 2024. The company’s Board of Directors, in their meeting on February 9, 2025, approved the unaudited financial results, announced a key managerial appointment, and introduced an employee stock option scheme (ESOP 2025).
Financial Performance Highlights (Q3 FY25 and 9M FY25)
Consolidated Financials (₹ in million)
| Particulars | Q3 FY25 (Dec 2024) | Q2 FY25 (Sep 2024) | Q3 FY24 (Dec 2023) | 9M FY25 | 9M FY24 | FY24 (Audited) |
|---|
| Revenue from Operations | 3,980.82 | 4,174.60 | 3,359.58 | 11,457.59 | 9,557.98 | 12,969.00 |
| Other Income | 132.74 | 112.73 | 86.09 | 364.81 | 242.87 | 370.64 |
| Total Income | 4,113.56 | 4,287.33 | 3,445.67 | 11,822.40 | 9,800.85 | 13,139.64 |
| EBITDA | 1,476.31 | 1,602.86 | 1,267.50 | 3,573.09 | 3,054.23 | 4,068.67 |
| Profit Before Tax (PBT) | 943.27 | 1,053.52 | 847.65 | 2,530.32 | 2,256.39 | 2,948.13 |
| Profit After Tax (PAT) | 689.41 | 790.05 | 625.73 | 1,876.74 | 1,672.22 | 2,182.87 |
| EPS (Basic & Diluted) (₹) | 6.76 | 7.77 | 6.12 | 18.43 | 16.36 | 21.38 |
- Revenue grew 18.5% YoY for Q3 FY25, reflecting strong operational performance.
- EBITDA margin stood at 35.9%, indicating efficient cost management.
- Net profit increased 10.2% YoY, driven by higher patient volumes and improved service mix.
Standalone Financials (₹ in million)
| Particulars | Q3 FY25 (Dec 2024) | Q2 FY25 (Sep 2024) | Q3 FY24 (Dec 2023) | 9M FY25 | 9M FY24 | FY24 (Audited) |
|---|
| Revenue from Operations | 3,815.65 | 4,039.25 | 3,217.90 | 11,005.12 | 9,108.05 | 12,365.62 |
| Total Income | 3,944.13 | 4,146.49 | 3,300.31 | 11,355.66 | 9,355.18 | 12,735.10 |
| Profit Before Tax (PBT) | 921.13 | 1,035.96 | 825.45 | 2,473.37 | 2,207.93 | 2,892.17 |
| Profit After Tax (PAT) | 669.75 | 773.44 | 611.41 | 1,830.45 | 1,644.55 | 2,148.91 |
| EPS (Basic & Diluted) (₹) | 6.60 | 7.62 | 6.03 | 18.03 | 16.20 | 21.17 |
Strategic Updates and Corporate Announcements
Appointment of New Company Secretary
- The Board approved the appointment of Ms. Shreya Mitra as the Company Secretary & Compliance Officer, effective February 9, 2025.
- Ms. Mitra, an associate member of the ICSI, brings over 8 years of experience in corporate secretarial compliances and IPO handling.
Launch of Employee Stock Option Scheme (ESOP 2025)
- The Board has approved the Rainbow Children’s Medicare Limited - Employee Stock Option Scheme 2025.
- Total Options: 10,15,000 stock options for eligible employees and subsidiaries.
- Pricing: Exercise price subject to a maximum 20% discount on the market price, but not below the face value of ₹10 per share.
- Vesting Period: Minimum 1 year, maximum 10 years.
- Exercise Window: 2 years post-vesting.
Regulatory Compliance & Materiality Authorization
- The Board has designated Dr. Ramesh Kancharla (CMD), Mr. Vikas Maheshwari (CFO), and Ms. Shreya Mitra (CS & Compliance Officer) as the key personnel authorized to determine the materiality of events under SEBI Listing Regulations.
Outlook & Future Growth Prospects
- Expansion Plans: Continued capital investments in new hospitals and medical equipment.
- Strong Financial Position: Unutilized IPO proceeds of ₹116.29 million remain available for expansion.
- Market Demand: Increasing demand for pediatric and maternal healthcare services is expected to drive future revenue growth.
Conclusion
Rainbow Children’s Medicare Limited continues its strong financial trajectory, demonstrating
double-digit revenue growth, improved profitability, and strategic workforce expansion. The ESOP 2025 plan further solidifies its commitment to talent retention, while investments in new hospitals position the company for sustained long-term growth. Investors can expect continued momentum as the company leverages its operational efficiencies and expanding healthcare footprint.